Treatment of inflammatory bowel disease (IBD) and the exploration of novel therapies represent an important research field. We established a short-time-intestinal-bowel model that could serve as an experimental test system that enables the investigation of early mucosal inflammation of IBD pathogenesis and a rapid screening of novel therapeutic options. Local mucosal inflammation is induced by an in situ perfusion of a defined segment of the small intestine with the sulfhydryl blocker iodoacetamide leading to an intestinal inflammation within two hours limited to the perfused segment only.